John Oyler filed Amendment No. 8 to a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 54,065,077 ordinary shares of BeOne Medicines Ltd. as of September 30, 2026.

Key Highlights

  • Total beneficial ownership: John Oyler reported aggregate beneficial ownership of 54,065,077 ordinary shares of BeOne Medicines Ltd.
  • Percent of class: The reported holdings represent 3.6% of the class, based on 1,483,318,035 ordinary shares outstanding as of September 30, 2026.
  • Directly held shares: Only 34,105 ordinary shares are held directly by Mr. Oyler.
  • Roth IRA holdings: 9,545,000 ordinary shares are held for Mr. Oyler's benefit in a Roth IRA PENSCO trust account.
  • Options and RSUs: 6,396,286 shares are issuable upon exercise of share options or restricted share units exercisable or vesting within 60 days after September 30, 2026.
  • Disclaimed interests: Mr. Oyler disclaims beneficial ownership of shares held by The John Oyler Legacy Trust, two grantor retained annuity trusts, Oyler Investment LLC, the P&O Trust, and a private foundation.

Breakdown of John Oyler's Reported BeOne Medicines Holdings

According to the filing, John Oyler's aggregate beneficial ownership of 54,065,077 ordinary shares of BeOne Medicines Ltd. consists of eight distinct components. The largest single block is 28,204,115 ordinary shares held by Oyler Investment LLC, with 99% of the limited liability company interest owned by a grantor retained annuity trust of which Mr. Oyler's father is a trustee. Mr. Oyler disclaims beneficial ownership of these shares. A second grantor retained annuity trust, also with Mr. Oyler's father as trustee, holds 7,699,158 ordinary shares, for which Mr. Oyler also disclaims beneficial ownership.

Beyond those structures, the filing reports 9,545,000 ordinary shares held in a Roth IRA PENSCO trust account for Mr. Oyler's benefit, and 6,396,286 shares issuable upon exercise of share options or restricted share units exercisable or vesting within 60 days after September 30, 2026. The filing also identifies 1,602,692 ordinary shares held by a private foundation of which Mr. Oyler, Victoria Pan, and others serve as directors, for which Mr. Oyler disclaims beneficial ownership, along with 481,533 shares in the P&O Trust and 102,188 shares in The John Oyler Legacy Trust, in each case with a disclaimer of beneficial ownership. Only 34,105 ordinary shares are described as held directly by Mr. Oyler.

The filing states that sole voting power and sole dispositive power over all 54,065,077 shares are attributed to Mr. Oyler, with no shared voting or dispositive power reported. The percent of class figure of 3.6% is based on 1,483,318,035 ordinary shares outstanding as of September 30, 2026, as reported by the issuer to the reporting person. The filing is designated as Amendment No. 8 and was signed by John Oyler on November 13, 2026.

What Was Disclosed

John Oyler filed Amendment No. 8 to Schedule 13G reporting 54,065,077 ordinary shares of BeOne Medicines Ltd. beneficially owned as of September 30, 2026, equal to 3.6% of the class, with the majority held through trusts and an LLC for which he disclaims beneficial ownership.